Prism Bio-Pharma Profile
Key Indicators
- Authorised Capital ₹ 1.00 M
- Paid Up Capital ₹ 0.20 M
- Company Age 4 Year, 10 Months
- Last Filing with ROC 31 Mar 2023
- Revenue Growth -26.41%
- Profit Growth 104.58%
- Ebitda 367.96%
- Net Worth 190.80%
- Total Assets 15.36%
About Prism Bio-Pharma
Prism Bio-Pharma Private Limited (PBPL) is a registered startup operating as a Private Limited Indian Non-Government Company incorporated in India on 16 March 2020 (Four years and ten months 18 days old ). Its registered office is in Ahmedabad, Gujarat, India.
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2023. It's a company limited by shares with an authorized capital of Rs 1.00 M and a paid-up capital of Rs 0.20 M, as per Ministry of Corporate Affairs (MCA) records.
Rajendra Patel and Vijaykumar Singh serve as directors at the Company.
Company Details
-
Location
Ahmedabad, Gujarat, India
-
Telephone
+91-XXXXXXXXXX
-
Email Address
-
Website
-
-
Social Media-
Corporate Identity Details
-
CIN/LLPIN
U24239GJ2020PTC113175
-
Company No.
113175
-
Company Classification
Private Limited Indian Non-Government Company
-
Incorporation Date
16 Mar 2020
-
Date of AGM
30 Sep 2023
-
Date of Balance Sheet
31 Mar 2023
-
Listing Status
Unlisted
-
ROC Code
Roc Ahmedabad
Industry
Who are the key members and board of directors at Prism Bio-Pharma?
Board Members (2)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Rajendra Patel
|
Director | 10-Jun-2024 | Current |
|
Vijaykumar Singh
|
Director | 07-May-2022 | Current |
Financial Performance of Prism Bio-Pharma.
Prism Bio-Pharma Private Limited, for the financial year ended 2023, experienced significant reduction in revenue, with a 26.41% decrease. The company also saw a substantial improvement in profitability, with a 104.58% increase in profit. The company's net worth Soared by an impressive increase of 190.8%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metrics |
|
(FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
|
||||||
| Revenue from Operations |
|
||||||
| Total Assets |
|
||||||
| Profit or Loss |
|
||||||
| Net Worth |
|
||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Prism Bio-Pharma?
Unlock access to Prism Bio-Pharma's control and ownership data, Corporate Shareholding Patterns, Funding (security allotment) details, Foreign Institutional Investor information, Directors and Key Management Personnel (KMP) Remuneration, Group Structure, Overseas Direct Investment and other pertinent data.
Related Corporates (Common Directorship)
-
Geniron Healthcare Private LimitedRajendra Patel is a mutual person
-
Excel Biolife Private LimitedRajendra Patel is a mutual person
Charges (Loans)
There are no open charges registered against the company as per our records.
How Many Employees Work at Prism Bio-Pharma?
Prism Bio-Pharma has a workforce of 0 employees as of Mar 27, 2024. Unlock access to detailed historical data on individuals associated with the company, including employment records, contributions to the Employees' Provident Fund Organization (EPFO), and other related insights.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Prism Bio-Pharma, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Prism Bio-Pharma's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
